FDA approves Rhapsido for chronic hives inadequately controlled by antihistamines
Novartis announced FDA approval of remibrutinib (Rhapsido) for adults with symptomatic dermographism not controlled by antihistamines. The approval was based on the RemIND trial, where 29.3% of patients achieved complete response vs. 14% on placebo. The drug is an oral, selective Bruton’s tyrosine kinase inhibitor. Common side effects include nasal congestion and headache.
How this was made
The 30-second read
Why it matters
The approval creates a first‑in‑class therapy for a condition affecting >90% of chronic hives patients, opening a sizable market and potentially boosting Novartis' dermatology revenues.
Market read
Regulatory approval is a primary catalyst that can move Novartis' stock and affect biotech sector sentiment.
What to watch
Reimbursement negotiations and market adoption rates could moderate impact.
Background
Novartis announced FDA approval of remibrutinib (Rhapsido) for adults with symptomatic dermographism inadequately controlled by H1 antihistamines, based on Phase 3 RemIND trial data.
Ticker impact
FDA approval of Novartis' remibrutinib (Rhapsido) for chronic hives provides a new, material product launch.
upward pressure as investors price in sales potential from the new indication.
First FDA approval for symptomatic dermographism, backed by positive Phase 3 data, creates a clear growth catalyst.
Market effects
Strengthens the biotech/dermatology sector as a new therapy enters market.
Potential uplift for US and European biotech indices.
Adds to global pipeline of BTK inhibitors, may influence competitor valuations.
Counterpoint
If market expectations were already high, price may already be baked in, limiting upside.
Key entities
- CompanyNovartis
Pharmaceutical company receiving FDA approval for remibrutinib.
- ProductRemibrutinib (Rhapsido)
Oral BTK inhibitor approved for chronic hives.
